PURPOSE: To investigate phosphoinositide kinase-3 (PI3K) activation in relation to human papillomavirus (HPV) status in head and neck squamous cell carcinoma (HNSCC). METHODS AND MATERIALS: Gene expression microarray data were analyzed to determine differentially expressed genes between HPV(+) and HPV(-) HNSCC. PIK3CA gene expression was confirmed by quantitative reverse transcriptase-polymerase chain reaction in seven HPV(+) and seven HPV(-) primary HNSCCs. PIK3CA mutation status in three HPV(+) and nine HPV(-) cell lines was determined by polymerase chain reaction amplification of hot spot exons (1, 9, 20) followed by direct sequencing. RESULTS: PIK3CA was overexpressed in HPV(+)-associated HNSCC compared with the expression in HPV(-) HNSCC. Activation of PIK3CA by mutation was found in 1 of the 12 tested HNSCC cell lines. CONCLUSION: Activation of PI3K by mutation of PIK3CA is rare in HNSCC cell lines and was not found in three HPV(+) cell lines. One mechanism by which HPV-associated HNSCC might activate PI3K is increased expression of PIK3CA.
PURPOSE: To investigate phosphoinositide kinase-3 (PI3K) activation in relation to human papillomavirus (HPV) status in head and neck squamous cell carcinoma (HNSCC). METHODS AND MATERIALS: Gene expression microarray data were analyzed to determine differentially expressed genes between HPV(+) and HPV(-) HNSCC. PIK3CA gene expression was confirmed by quantitative reverse transcriptase-polymerase chain reaction in seven HPV(+) and seven HPV(-) primary HNSCCs. PIK3CA mutation status in three HPV(+) and nine HPV(-) cell lines was determined by polymerase chain reaction amplification of hot spot exons (1, 9, 20) followed by direct sequencing. RESULTS:PIK3CA was overexpressed in HPV(+)-associated HNSCC compared with the expression in HPV(-) HNSCC. Activation of PIK3CA by mutation was found in 1 of the 12 tested HNSCC cell lines. CONCLUSION: Activation of PI3K by mutation of PIK3CA is rare in HNSCC cell lines and was not found in three HPV(+) cell lines. One mechanism by which HPV-associated HNSCC might activate PI3K is increased expression of PIK3CA.
Authors: Ryan T Anderson; Stephen B Keysar; Daniel W Bowles; Magdalena J Glogowska; David P Astling; J Jason Morton; Phuong Le; Adrian Umpierrez; Justin Eagles-Soukup; Gregory N Gan; Brian W Vogler; Daniel Sehrt; Sarah M Takimoto; Dara L Aisner; Francois Wilhelm; Barbara A Frederick; Marileila Varella-Garcia; Aik-Choon Tan; Antonio Jimeno Journal: Mol Cancer Ther Date: 2013-07-19 Impact factor: 6.261
Authors: Andrew Sewell; Brandee Brown; Asel Biktasova; Gordon B Mills; Yiling Lu; Darren R Tyson; Natalia Issaeva; Wendell G Yarbrough Journal: Clin Cancer Res Date: 2014-03-05 Impact factor: 12.531
Authors: Toni M Brand; Stefan Hartmann; Neil E Bhola; Hua Li; Yan Zeng; Rachel A O'Keefe; Max V Ranall; Sourav Bandyopadhyay; Margaret Soucheray; Nevan J Krogan; Carolyn Kemp; Umamaheswar Duvvuri; Theresa LaVallee; Daniel E Johnson; Michelle A Ozbun; Julie E Bauman; Jennifer R Grandis Journal: Cancer Res Date: 2018-02-12 Impact factor: 13.312
Authors: Michael Hajek; Andrew Sewell; Susan Kaech; Barbara Burtness; Wendell G Yarbrough; Natalia Issaeva Journal: Cancer Date: 2017-03-13 Impact factor: 6.860
Authors: Amy T Shah; Michelle Demory Beckler; Alex J Walsh; William P Jones; Paula R Pohlmann; Melissa C Skala Journal: PLoS One Date: 2014-03-04 Impact factor: 3.240
Authors: Matthias Lechner; Garrett M Frampton; Tim Fenton; Andrew Feber; Gary Palmer; Amrita Jay; Nischalan Pillay; Martin Forster; Maureen T Cronin; Doron Lipson; Vincent A Miller; Timothy A Brennan; Stephen Henderson; Francis Vaz; Paul O'Flynn; Nicholas Kalavrezos; Roman Yelensky; Stephan Beck; Philip J Stephens; Chris Boshoff Journal: Genome Med Date: 2013-05-29 Impact factor: 11.117